Understanding how MyD88 activation affects Sjögren’s disease
Analysis of MyD88-mediated activation in Sjogren’s disease
This study is looking at how a protein called MyD88 affects the development of Primary Sjögren’s disease, which mainly impacts women and causes uncomfortable symptoms like dry eyes and mouth, with the goal of finding new ways to diagnose and treat this condition better.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | State University of New York at Buffalo NIH-funded |
| Lab location | 1 site (Amherst, United States) |
| Project ID | NIH-11132322 on NIH RePORTER |
What this research studies
This research investigates the role of MyD88, a protein involved in immune responses, in the development of Primary Sjögren’s disease (pSD), an autoimmune condition that primarily affects women. The study aims to uncover the mechanisms behind pSD, which leads to symptoms like dry eyes and mouth due to damage to exocrine tissues. By focusing on MyD88-dependent pathways, the researchers hope to identify potential therapeutic targets that could lead to earlier diagnosis and better treatment options for patients suffering from this debilitating disease.
Who could benefit from this research
Good fit: Ideal candidates for this research are women diagnosed with Primary Sjögren’s disease who experience symptoms such as dry eyes and mouth.
Not a fit: Patients with other autoimmune diseases not related to Sjögren’s disease may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new treatments that specifically target the underlying causes of Sjögren’s disease, improving patient outcomes.
How similar studies have performed: Previous research has shown success in targeting MyD88 pathways in other autoimmune disorders, suggesting potential for similar advancements in Sjögren’s disease.
Where this research is happening
Amherst, United States
- State University of New York at Buffalo — Amherst, United States (Active)
Researchers
- Principal investigator: Kramer, Jill Marie — State University of New York at Buffalo
- Study coordinator: Kramer, Jill Marie
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.